Serial serum MCA measurements in the follow-up of breast cancer patients

Merimsky, Ofer; Inbar, Moshe; Hareuveni, Mara; Witenberg, Bruria; Wolman, Yoram; Chaitchik, Samario

doi:10.1016/0277-5379(91)90027-b

Cited by 11 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, significant increases of MCA-CA15.3 association occurred more frequently (60% vs 31%) or similarly (29% vs 31%) to those of CEA-TPA-CA15.3 tumour marker panel. This finding does not confirm that MCA specificity is similar to or higher than that of CEA and CA15.3 [17,20-23]. Moreover, our results show that in non relapsed patients the aspecific reasons probably responsible for MCA increase are the same as for TPA.…”

Section: Discussioncontrasting

confidence: 83%

“…The mucin-like carcinoma associated antigen (MCA) is another widely used test to assay MUC-1. When it has been used alone, high sensitivity and specificity have been reported [17,20,21]. This suggests the association with CA15.3.…”

Section: Introductionmentioning

confidence: 99%

“…This suggests the association with CA15.3. However, different cut-off values have been reported for MCA [17,20]. Besides conflicting data have been found both as to MCA sensitivity and specificity compared to CA15.3 [22-25] and the MCA-CA15.3 usefulness [14,15,22,26,27].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

et al. 2006

View full text Add to dashboard Cite

Background: In breast cancer current guidelines do not recommend the routine use of serum tumour markers. Differently, we observed that CEA-TPA-CA15.3 (carcinoembryonic (CEA) tissue polypeptide (TPA) and cancer associated 115D8/DF3 (CA15.3) antigens) panel permits early detection and treatment for most relapsing patients. As high sensitivity and specificity and different cut-off values have been reported for mucin-like carcinoma associated antigen (MCA), we compared MCA with the above mentioned tumour markers and MCA-CA15.3 with the CEA-TPA-CA15.3 panel. Methods:In 289 breast cancer patients submitted to an intensive post-operative follow-up with tumour markers, we compared MCA (cut-off values, ≥ 11 and ≥ 15 U/mL) with CEA or CA15.3 or TPA for detection of relapse. In addition, we compared the MCA-CA15.3 and CEA-TPA-CA15.3 tumour marker panels. Results: Distant metastases occurred 19 times in 18 (6.7%) of the 268 patients who were disease-free at the beginning of the study. MCA sensitivity with both cut-off values was higher than that of CEA or TPA or CA15.3 (68% vs 10%, 26%, 32% and 53% vs 16%, 42%, 32% respectively). With cut-off ≥ 11 U/mL, MCA showed the lowest specificity (42%); with cut-off ≥ 15 U/mL, MCA specificity was similar to TPA (73% vs 72%) and lower than that of CEA and CA15.3 (96% and 97%

show abstract

Section: Discussioncontrasting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

et al. 2006

View full text Add to dashboard Cite

show abstract

“…When CA15.3 was compared to CEA, about a 10-30% higher incidence of elevated CA15.3 versus CEA was found in metastatic disease and in the early diagnosis of distant metastases [13,28,29,[31][32][33]. Among the other TAA reported, tissue polypeptide antigen (TPA) and the mucin-like carcinomaassociated antigens MCA and CA549 seem to be the most interesting due to their high sensitivity, ranging from 70-91% in active metastatic disease [34][35][36][37]. Nevertheless, in many follow-up studies, sensitivity refers to the presence of established metastatic disease, and the lead time between the tumor marker increase and the positive clinical and/or conventional instrumental examinations was not well defined.…”

Section: Clinical Diagnosis Of Distant Metastases: Tumor Markersmentioning

confidence: 99%

“…Thus false-positive results of tumor markers decrease the diagnostic accuracy and increase the follow-up costs. In breast cancer patients, CEA and CA15.3 are reported to falsely signal recurrences in 8 and 12% of the patients, respectively [13], while TPA, MCA and CA549 were false positive in 10-40% of the patients [34][35][36][37]. At present, few single markers have proved to have sufficiently high sensitivity and specificity to permit early detection with accuracy of most recurrences as PSA in prostate cancer, ·-fetoprotein in hepatocarcinoma, ß-HCG in testicular cancer and choriocarcinoma and thyroglobulin in differentiated thyroid cancer.…”

Section: Clinical Diagnosis Of Distant Metastases: Tumor Markersmentioning

confidence: 99%

Postoperative Follow-Up of Breast Cancer Patients: Overview and Progress in the Use of Tumor Markers

Nicolini¹,

Carpi²

2000

Tumor Biology

View full text Add to dashboard Cite

The role of serial measurement of serum tumor-associated antigens (TAA) in the postoperative follow-up of breast cancer patients is not considered by most authors. The authors of this article review the literature and original data showing benefits from the use of TAA in the postoperative follow-up of breast cancer patients. An increase in the lead time from the first pathological finding to the definite evidence of distant metastases has been observed in follow-up studies which have used TAA compared to those which did not use them. The sensitivity and specificity of TAA in the diagnosis of distant metastases have been markedly improved by selecting an appropriate combination of TAA and by identifying specific conditions associated with breast cancer responsible for false-positive results as well as by adopting a ‘dynamic’ evaluation of multiple successive determinations of TAA. TAA accurately predict patients with bone metastases and can be used to guide imaging techniques. The anticipation of distant metastasis by TAA can be used to initiate a relatively early treatment which has been shown to prolong overall survival in a previous study. It is hoped that these data will stimulate further trials including TAA in the follow-up of breast cancer patients.

show abstract

Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial

Kovner

Merimsky

Hareuveni

et al. 1994

Cancer Chemother. Pharmacol.

View full text Add to dashboard Cite

Increasing levels of tumor markers such as carcinoembryonic antigen, mucin-like carcinoma-associated antigen (MCA), CA 15.3, and monoclonal antibody H23 in breast cancer patients following the treatment of the primary disease and adjuvant radiation and chemotherapy reflect subclinical development of metastatic disease. Overt metastatic disease is usually incurable and prolongation of life at this stage is impossible, and the treatment is only palliative. The efficacy of tamoxifen, a least-toxic agent, in the treatment of early and minimal metastatic disease detected only by increasing serum levels of MCA was studied prospectively in a randomized study. Our preliminary, albeit encouraging, results showed that the rate of relapse within a median follow-up period of 11 months was 24.1% in the control arm as compared with 0% in the tamoxifen arm (Fisher's exact test, P = 0.012). None of the patients with a relapse had positive progesterone receptors (PR). We may carefully conclude that early treatment may be warranted in young patients with negative PR and continuously increasing serum levels of the marker.

show abstract

Serial serum MCA measurements in the follow-up of breast cancer patients

Cited by 11 publications

References 7 publications

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

Postoperative Follow-Up of Breast Cancer Patients: Overview and Progress in the Use of Tumor Markers

Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial

Contact Info

Product

Resources

About